Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E10.42 EPS (ttm)21.72 Insider Own0.10% Shs Outstand199.80M Perf Week-3.18%
Market Cap45.23B Forward P/E7.62 EPS next Y29.72 Insider Trans39.61% Shs Float195.78M Perf Month-29.38%
Income4.45B PEG2.63 EPS next Q6.84 Inst Own93.50% Short Float1.46% Perf Quarter-33.09%
Sales13.45B P/S3.36 EPS this Y24.50% Inst Trans0.08% Short Ratio1.28 Perf Half Y-33.14%
Book/sh65.26 P/B3.47 EPS next Y3.39% ROA17.60% Target Price261.12 Perf Year-15.54%
Cash/sh17.71 P/C12.78 EPS next 5Y3.96% ROE33.40% 52W Range216.12 - 388.67 Perf YTD-24.77%
Dividend- P/FCF7.45 EPS past 5Y22.70% ROI23.60% 52W High-41.75% Beta1.04
Dividend %- Quick Ratio2.00 Sales past 5Y14.20% Gross Margin86.50% 52W Low4.75% ATR8.67
Employees7800 Current Ratio2.30 Sales Q/Q6.60% Oper. Margin43.80% RSI (14)28.95 Volatility2.33% 3.02%
OptionableYes Debt/Eq0.46 EPS Q/Q17.00% Profit Margin32.90% Rel Volume1.20 Prev Close227.18
ShortableYes LT Debt/Eq0.46 EarningsApr 24 BMO Payout0.00% Avg Volume2.24M Price226.39
Recom2.80 SMA20-2.50% SMA50-21.06% SMA200-29.31% Volume2,673,362 Change-0.35%
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Feb-21-19Downgrade Stifel Buy → Hold $397 → $346
Dec-21-18Initiated BTIG Research Buy
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Apr-18-19 10:29AM  Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs Zacks
Apr-17-19 02:34PM  Here's Why Ionis Pharmaceuticals Slumped Today Motley Fool
01:45PM  2 Beaten Down Bluechips: Are They Buys? Motley Fool
10:31AM  Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-15-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
03:00PM  Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
06:58AM  Goldman Sachs's 20 best stocks to invest in now Yahoo Finance
Apr-14-19 09:16AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Apr-12-19 07:30AM  Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference GlobeNewswire
Apr-11-19 06:33AM  Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace
12:00AM  An AI Firm Wants to Predict Costly Pharma Flops Bloomberg
Apr-10-19 09:59AM  Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds Benzinga
Apr-09-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
05:01PM  6 Predictable Guru Stocks GuruFocus.com
Apr-07-19 11:59PM  Sarissa Capital Management Hires New President Insider Monkey
Apr-06-19 06:13PM  Should Biogen Investors Be Extra Nervous Right Now? Motley Fool
Apr-04-19 03:54PM  Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us Simply Wall St.
02:49PM  1 Biotech That Biogen Should Buy ... but Probably Won't Motley Fool
01:28PM  Buy Biogen on the dip? What about AMC on the streaming wars? The viewers #AskHalftime CNBC Videos
09:57AM  Why Biogen Stock Tanked in March Motley Fool
09:03AM  MOVES-Activist hedge fund Sarissa hires president in push for growth Reuters
Apr-03-19 06:08PM  Biogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group Reuters
05:41PM  Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters
04:37PM  Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters
08:21AM  Why Nightstar Therapeutics Stock Skyrocketed 71% in March Motley Fool
Apr-02-19 11:58AM  3 Healthcare Stocks to Trade Now InvestorPlace
10:10AM  Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks
Apr-01-19 04:24PM  Celgene Gets Positive CHMP Nod for Revlimid Label Expansion Zacks
02:56PM  These are the 20 most valuable brands in Massachusetts American City Business Journals
01:46PM  3 High Earnings-Yield Stocks GuruFocus.com
10:41AM  Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval Zacks
Mar-30-19 12:00PM  3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool
05:46AM  Are the health care stocks flat lining? Here are the beaten down names traders are still buying CNBC Videos
Mar-29-19 10:36AM  4 Small Biotech Stocks Likely to Witness More Upside in 2019 Zacks
Mar-28-19 04:34PM  Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks? Motley Fool
12:04PM  Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining Motley Fool
Mar-27-19 07:19PM  The 5 Worst-Performing Stocks in the S&P 500 in 2019 GuruFocus.com
07:07PM  3 High-Quality, Low Price-Earnings Companies Broadly Owned by Gurus GuruFocus.com
06:50PM  Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey
06:13PM  Novartis (NVS) Receives FDA Approval for MS Drug Mayzent Zacks
04:12PM  The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval Investor's Business Daily
10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
10:00AM  Future Brightens for 2 Small Biotech Stocks TheStreet.com
07:00AM  Biogen Remains a Wide-Moat Neurology Innovator Morningstar
06:00AM  Biogen- A Bad News Biotech Buy MoneyShow
Mar-26-19 05:15PM  Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks +5.74%
04:28PM  Why Viacom, Ferroglobe, and Biogen Jumped Today Motley Fool
12:51PM  Stocks - Dow Ends Higher, but Gains Capped by Weak Economic Data Investing.com
11:18AM  AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan Zacks
10:24AM  Biogen's Bad News for Everyone Motley Fool
07:25AM  Detailed Research: Economic Perspectives on Biogen, Invesco, Bunge, Concho Resources, Maximus, and Meredith What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-25-19 04:24PM  Dow Ends Slightly Higher Despite Slowing Global Growth Worries TheStreet.com
03:15PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
02:48PM  1 Surprising Reason Alzheimer's Drugs Remain So Elusive Motley Fool
12:04PM  Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group Investor's Business Daily
10:39AM  Biogen Stock Likely Wont See a Boost From Buybacks, Analysts Say Barrons.com
09:56AM  Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters
09:41AM  Biogen Announces $5 Billion Buyback Just Days After Stock Plunge TheStreet.com
09:01AM  Avon and Biogen Gain, and 3 Other Stocks Making Moves Barrons.com
08:49AM  5 biotech stocks that could be the next big winners MarketWatch
08:32AM  Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters
07:26AM  Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge MarketWatch
06:55AM  Biogen stock plummets 28% after company halts Alzheimers trials MarketWatch
04:05AM  Stocks - Viacom Jumps in Premarket, Nike, Apple Drop, Boeing Gains Investing.com
Mar-24-19 01:00PM  Is It Safe to Buy Biogen Stock Right Now? InvestorPlace
Mar-23-19 12:20PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
10:02AM  2 Biotech Takeout Targets Perfect for Biogen Motley Fool
Mar-22-19 06:00PM  Primecap's Biogen Exposure Could Be History Repeating Morningstar
04:47PM  Biogen Skids On Alzheimer's Flop And Unveils Yet Another Study Investor's Business Daily
04:17PM  Current Stock Market Reverses Lower But Apple, Amazon Strong; Boeing 737 Max Probe; Biogen Dives: Weekly Review Investor's Business Daily
01:30PM  Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About' Benzinga
10:58AM  Biogen Stock Is Falling Again Because Even a Massive Plunge Doesnt Make it a Bargain Buy Barrons.com
10:57AM  Biogen Stock Crashes on Termination of Alzheimer's Studies Zacks
10:20AM  Biogen Stock Fell Too Far on Unfortunate News InvestorPlace
10:15AM  Company News For Mar 22, 2019 Zacks
10:15AM  PMN.TO: Aducanumab Failed. What Does This Mean for Amyloid Beta? Zacks Small Cap Research
09:55AM  Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback Benzinga
09:30AM  Biogen stock price target cut to $247 from $341 at SVB Leerink MarketWatch
08:57AM  Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Atena CEO CNBC
08:44AM  Biogen stock downgraded to neutral from buy at UBS MarketWatch
07:56AM  Former Aetna CEO Mark Bertolini on 'Medicare for All': No... CNBC Videos
07:30AM  A $28 Billion Shopping List for Biogen Bloomberg
07:26AM  Biogen and Apples 2000 Crash Share a Common Trait: Taking Stock Bloomberg
07:00AM  Biogens Next Move Could Be an Acquisition Barrons.com
06:28AM  Experts question Alzheimer's treatment strategy after Biogen failure American City Business Journals
05:01AM  Podcast: A 30% Drop for Biotech Company Biogen, and Two Other Numbers You Need to Know Barrons.com
02:05AM  Eisai starts phase 3 trials for second Alzheimer's drug after first's failure Reuters
12:15AM  Asian stocks stumble on doubts over US-China trade deal Associated Press
Mar-21-19 10:45PM  Nikkei falls as financials drag; Eisai indicated to dive Reuters -29.23%
09:05PM  Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials Reuters
05:41PM  The S&P 500 Eked Out a Gain Despite Biogens 29% Plunge Barrons.com
05:05PM  Stock Market Today: Biogen Crushed After Failure of Alzheimer's Drug Motley Fool
05:00PM  Is Biogen a Bad-News Buy Now? Motley Fool
04:47PM  Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value Reuters
04:44PM  Biogen analyst breaks down what investors want from the c... CNBC Videos
04:31PM  US STOCKS-Wall Street rises as Apple, tech shares climb Reuters
04:29PM  Biogen and Guess slide while Darden and Micron rise Associated Press
04:27PM  Biogen Crashes On Alzheimer's Flop Is Its Remaining Pipeline A Dud? Investor's Business Daily
04:26PM  Dow Ends Solidly Higher as Investors Shrug Off Fed Warning of Slowing Growth TheStreet.com
03:58PM  Biogen halted trial could boost M&A activity, says analys... CNBC Videos
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM